GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biote BTMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.84

-4.65%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Biote — daily BTMD Delayed
Market value
$38.6m
Last close × shares
Volume
62.9k
Shares, 19 Nov 2026
Price to earnings
1.5

About Biote

From its filings with the US Securities and Exchange Commission

SEC filings

Biote is based in Irving, Texas. Its shares trade on Nasdaq under the ticker BTMD. The SEC classifies its business as medicinal chemicals & botanical products. In the fiscal year to 31 December 2025, it reported revenue of $192.2m and net income of $27.0m. At that date it held total assets of $107.6m and shareholders' equity of −$58.5m.

In its own words

We operate a high-growth practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the following components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (“HRT”) products, as well as digital and point-of-care marketing support. We also sell a complementary Biote-branded line of dietary supplements. We generate revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements. By virtue of our historical performance over the past 14 years, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth.

Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗

More about Biote →

How it makes its money

Revenue, year to 31 Dec 2025

  • Product Revenue $186.9m · 97.2%
  • Pellet Procedures Product Revenue $137.0m · 71.3%
  • Dietary Supplements $42.9m · 22.3%
  • Disposable Trocars Product Revenue $4.9m · 2.5%

Latest on Biote

Our reporting

Next results

10 Mar 2027

Due on 10 Mar 2027. Analysts expect earnings of -0.03 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Biote's ticker?

Biote trades as BTMD on its US listing, under ISIN US0906831039.

What was Biote's last closing price?

0.84 on 19 Nov 2026. The figure is in USD and is never converted.

When does Biote next report results?

Results are expected on 10 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.